Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash & Current Investments (2016 - 2025)

Coherus Oncology's Cash & Current Investments history spans 13 years, with the latest figure at $172.1 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 36.62% year-over-year to $172.1 million; the TTM value through Dec 2025 reached $172.1 million, up 36.62%, while the annual FY2025 figure was $172.1 million, 36.62% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $172.1 million at Coherus Oncology, down from $191.7 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $468.7 million in Q3 2021 and bottomed at $82.4 million in Q1 2025.
  • The 5-year median for Cash & Current Investments is $191.7 million (2022), against an average of $233.4 million.
  • The largest annual shift saw Cash & Current Investments skyrocketed 106.73% in 2021 before it plummeted 68.28% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $417.2 million in 2021, then crashed by 54.05% to $191.7 million in 2022, then crashed by 38.57% to $117.7 million in 2023, then increased by 7.0% to $126.0 million in 2024, then soared by 36.62% to $172.1 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Cash & Current Investments are $172.1 million (Q4 2025), $191.7 million (Q3 2025), and $237.6 million (Q2 2025).